Investigating how a protein affects blood vessel cells in lung disease
Official title: Role of Epigenetic Regulator SIN3a in Pulmonary Endothelial Cells
Funded at Icahn School of Medicine at Mount Sinai · NIH-10990338 · Data updated 2026-11-12
This study is looking at a protein called SIN3a in lung cells to see how it affects another protein that helps keep your blood vessels healthy, with the hope of finding new treatments for people with pulmonary arterial hypertension (PAH).
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 15, 2024 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $814,462 |
| NIH project number | 1R01HL172043-01A1 |
| Project ID | NIH-10990338 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension, particularly those with mutations affecting the BMPR2 gene.
✕Less likely to help
Patients with pulmonary arterial hypertension who do not have any genetic mutations related to BMPR2 may not benefit from this research.
What this research studies
This research focuses on pulmonary arterial hypertension (PAH), a serious lung condition that leads to high blood pressure in the lungs and can cause heart failure. The study examines the role of a protein called SIN3a in pulmonary endothelial cells, which are crucial for maintaining healthy blood vessels. By understanding how SIN3a influences the gene that regulates another important protein, BMPR2, the research aims to uncover new therapeutic strategies to restore normal function in these cells. Patients may benefit from insights that could lead to innovative treatments for PAH.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve the health and survival of patients with pulmonary arterial hypertension.
How similar studies have gone: Previous research has shown promising results in targeting epigenetic regulators for therapeutic purposes, suggesting potential success for this approach.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Hadri, Lahouaria — Icahn School of Medicine at Mount Sinai
- Study coordinator: Hadri, Lahouaria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.